Form D · Biotechnology

AETHLON MEDICAL INC

San Diego, CA · CIK 0000882291

Offering snapshot reported Dec 23, 2025 · SEC filing

Reported sold
$2.15M
Offering amount: $2.15M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 8, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 23, 2025Initial$2,153,700No comparison1SEC filing
Jan 24, 2020Initial$2,733,797No comparison7SEC filing
Jul 9, 2015Initial$6,000,000No comparison19SEC filing
Dec 15, 2014Initial$3,300,000No comparison4SEC filing
Nov 21, 2014Initial$527,780No comparison2SEC filing
Nov 4, 2014Initial$837,737No comparison3SEC filing
Nov 4, 2014Initial$838,725No comparison9SEC filing
Nov 4, 2014Initial$913,500No comparison14SEC filing
Jan 9, 2014Amendment$1,795,900$270,000vs Dec 20, 201322SEC filing
Dec 20, 2013Amendment$1,525,900$883,900vs Nov 22, 201319SEC filing
Nov 22, 2013Amendment$642,000$412,000vs Nov 12, 201311SEC filing
Nov 12, 2013Initial$230,000No comparison3SEC filing
Oct 11, 2013Amendment$2,037,834$996,834vs Oct 25, 201227SEC filing
Sep 16, 2013Initial$400,000No comparison2SEC filing
Oct 25, 2012Initial$1,041,000No comparison15SEC filing
Feb 29, 2012Amendment$1,050,000$525,000vs Dec 2, 201110SEC filing
Dec 2, 2011Amendment$525,000$315,000vs Nov 21, 20115SEC filing
Nov 21, 2011Initial$210,000No comparison1SEC filing
May 19, 2011Initial$350,000No comparison2SEC filing
Sep 17, 2010Initial$650,000No comparison3SEC filing
Jul 30, 2010Initial$890,000No comparison1SEC filing
Feb 25, 2010Initial$600,000No comparison1SEC filing
Sep 3, 2009Initial$300,000No comparison1SEC filing
Sep 3, 2009Initial$307,500No comparison2SEC filing
Jan 12, 2009PaperNot reportedNo comparisonNot reportedSEC filing
Jan 12, 2009PaperNot reportedNo comparisonNot reportedSEC filing
Aug 26, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jun 4, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jan 7, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Aug 14, 2007PaperNot reportedNo comparisonNot reported

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$215K (estimated)
Finders' fees
$0
Form D file number
021-567976
Maxim Group, LLC has the option to subscribe for and purchase up to 96,059 shares of Common Stock.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANoneMaxim Group, LLC · CRD 120708

Source: Form D, filed Dec 23, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Franklyn S. Barry, Jr. Director
Edward G. Broenniman Director
Edawrd G. Broenniman Director
Guy Cipriani Director
Charles J. Fisher Director
James B. Frakes Director, Executive
Nicolas Gikakis Director
James A. Joyce Director, Executive
Rodney S. Kenley Director, Executive
Sabrina Martucci Johnson Director
Timothy C. Rodell Director, Executive
Angela Rossetti Director
Chetan S. Shah Director
Chetan S. Shah, Md Director
Chetan S. Shah, M.D. Director
Richard H. Tullis Director, Executive
Richard H. Tullis, Ph D Executive
Richard H. Tullis, Ph.D. Director, Executive
Richard H. Tulls, Ph D Director, Executive
Phillip Ward Director
Thomas Wornham Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
11555 Sorrento Valley Road, Suite 203 Suite 203
San Diego, CA, 92121